Results 221 to 230 of about 19,667,204 (333)

Pre‐admission beta‐blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock‐2 Registry

open access: yesESC Heart Failure, EarlyView.
Among 668 with cardiogenic shock included in the multicentre prospective Altshock‐2 registry, 299 patients (44.8%) received pre‐admission beta‐blocker therapy. Previous beta‐blocker therapy influenced the early hemodynamic response to vasoactive drugs, but it was not associated with in‐hospital mortality.
Matteo Pagnesi   +21 more
wiley   +1 more source

Distinct troponin C isoform requirements in cardiac and skeletal muscle

open access: yesDevelopmental Dynamics, 2010
Vanessa M Sogah   +5 more
semanticscholar   +1 more source

Neuronal Nitric-oxide Synthase Interaction with Calmodulin-Troponin C Chimeras [PDF]

open access: hybrid, 1998
Ratan Gachhui   +7 more
openalex   +1 more source

Solution structure of the TR1C fragment of skeletal muscle troponin-C.

open access: hybrid, 1994
Wendy A. Findlay   +2 more
openalex   +1 more source

Pantethine therapy dramatically rescues end‐stage failing heart in a patient with deficiency of coenzyme A biosynthesis

open access: yes
ESC Heart Failure, EarlyView.
Violette Goetz   +9 more
wiley   +1 more source

METAB‐HTX: prospective, longitudinal cohort study evaluating cardiac and systemic metabolism after heart transplantation

open access: yesESC Heart Failure, EarlyView.
The METAB‐HTX trial is a prospective cohort study, evaluating cardiac and systemic metabolism among heart transplant recipients. Myocardial function, energetic and metabolism, allograft vasculopathy, allograft rejection, glucometabolism, lipometabolism, liver‐ and kidney function, leucocyte signatures and thromboinflammation will be evaluated ...
Amin Polzin   +21 more
wiley   +1 more source

HIF1α-dependent mitophagy facilitates cardiomyoblast differentiation [PDF]

open access: yes, 2020
Allen, George F. G.   +4 more
core   +2 more sources

Lower left ventricular ejection time in MYBPC3 variant carriers with overt or subclinical hypertrophic cardiomyopathy

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Hypertrophic cardiomyopathy (HCM) is an inherited cardiomyopathy often caused by pathogenic variants in MYBPC3 and MYH7, encoding myosin‐binding protein C3 and myosin heavy chain 7, respectively. These variants can cause increased actin–myosin crossbridge cycling, resulting in ventricular hypercontractility, but mice lacking Mybpc3 ...
Isabell Yan   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy